Glenmark Pharma arm to launch breast cancer treatment injection in US market

Glenmark Pharma’s US arm will launch Eribulin Mesylate Injection, a complex generic for breast cancer treatment, in September 2025.

Leave a Reply

Your email address will not be published. Required fields are marked *